Andrea Corbingi
YOU?
Author Swipe
View article: Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351. Open
CPX-351, a novel liposomal formulation of cytarabine and daunorubicine, represents the standard of care in fit patients with myelodysplasia-related changes (AML-MRC) and therapy-related Acute Myeloid Leukemia (tAML). Considering its better…
View article: Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory <scp> <i>FLT3</i> </scp> ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients
Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory <span> <i>FLT3</i> </span> ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients Open
Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3 ‐mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later‐line settings…
View article: A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemia
A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemia Open
This study provides a comprehensive analysis of the germline landscape in 81 families with chronic lymphocytic leukemia (CLL). We uncovered key genetic pathways associated with CLL predisposition, including telomere maintenance, DNA double…
View article: Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study Open
Familial chronic lymphocytic leukemia (CLL) constitutes 5% to 7% of CLL and has previously shown a more aggressive pattern of evolution than sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter c…
View article: Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience
Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience Open
In recent years, treatment of chronic lymphocytic leukemia(CLL) has changed considerably, in favor of a tailored and chemo-free approach, with the introduction of target drugs, such as BTK inhibitors (BTKi). Continuous BTKi, thanks to a pr…
View article: Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study
Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study Open
Introduction: Treatment of therapy-related AML (t-AML) and AML evolving from an antecedent myelodysplastic syndrome (AML-MRC) represent a clinical unmet need being characterized by an unfavorable outcome. Among the emerging treatment optio…
View article: Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study Open
Background: CPX-351, has been approved for the treatment of patients diagnosed with Acute Myeloid Leukemia (AML) arising from a previous myelodysplastic syndrome (s-AML) or secondary to chemotherapy (t-AML) as per former WHO 2016 classific…
View article: Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect
Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect Open
Gilteritinib is currently approved for patients with relapsed/refractory AML with FLT3 mutations, based on the positive results of the pivotal ADMIRAL study. In ADMIRAL trial, no increased risk of bleeding was reported, but in the previous…
View article: Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization?
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? Open
Allogeneic peripheral blood stem cells mobilization is now the basis of most stem cell transplants. In a very limited number of cases, mobilization is suboptimal leading to further collection procedures, to suboptimal cell doses infusion w…
View article: Prevention of postoperative anemia in hip hemiarthroplasty for femoral neck fractures: comparison between local haemostatic agents
Prevention of postoperative anemia in hip hemiarthroplasty for femoral neck fractures: comparison between local haemostatic agents Open
Background Tranexamic acid and fibrin sealant have been shown to be effective in reducing the need for transfusion after hip fracture surgery. Objective The aim of this study was to evaluate the efficacy of local haemostatic agents to redu…
View article: Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors Open
Background Germ cell tumors represent, among solid cancers, a potentially curable disease even if up to 20% to 30% of patients (pts) relapse after first‐line treatment especially considering intermediate and poor prognosis groups. In this …
View article: Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies Open
We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23‐55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. Wi…
View article: Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia Open
Summary The relationship between chronic lymphocytic leukaemia (CLL) and qualitative/quantitative gammaglobulin abnormalities is well established. Nevertheless, in order to better understand this kind of connection, we examined 1505 patien…
View article: PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON
PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON Open
Background: Allogeneic stem cell transplantation (HSCT) from an HLA identical sibling donor(SIB) remains standard of care. When a SIB donor is lacking, HLA mismatched related donors (HAPLO) are a valid alternative source of stem cells. The…
View article: PF392 MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE
PF392 MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE Open
Background: Chronic Lymphocytic Leukemia (CLL) is an indolent B‐cell lymphoproliferative disorder. Several prognostic factors such as IGHV mutation status and chromosomal aberrations as trisomy 12, del11q, del13q or del17p have been detect…
View article: PB1914 PURGING WITH CHLORAMBUCIL TO PREVENT INFUSION-RELATED REACTIONS BEFORE OBINUTUZUMAB ADMINISTRATION: A MONOCENTRIC PILOT EXPERIENCE.
PB1914 PURGING WITH CHLORAMBUCIL TO PREVENT INFUSION-RELATED REACTIONS BEFORE OBINUTUZUMAB ADMINISTRATION: A MONOCENTRIC PILOT EXPERIENCE. Open
Background: The efficacy and safety of Obinutuzumab (G), in combination with chlorambucil (Clb-G) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and comorbidities was demonstrated in the CLL11 study by improved progres…